Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
about
Identification of essential genes in the human fungal pathogen Aspergillus fumigatus by transposon mutagenesis.Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditisSpecific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma samplingRandomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Surgery of pulmonary aspergillomas in immunocompromised patients.Pharmacotherapy of Candida bloodstream infections: new treatment options, new era.Translation elongation-3-like factors: are they rational antifungal targets?Human pharmacogenomic variations and their implications for antifungal efficacy.The first echinocandin: caspofungin.Aspergillosis in a 24-week newborn: a case report.Phase II dose escalation study of caspofungin for invasive Aspergillosis.Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.Clinical impact of the fungicidal activity of caspofungin administered alone or in combination in critically ill patients with severe abdominal candidiasis refractory to conventional antifungal drugs: case studies and critical review of the problem.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Experience with caspofungin in the treatment of persistent fungemia in neonates.Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosisThe pharmacology and clinical use of caspofungin.The use of caspofungin in HIV-infected individuals.Clinical pharmacology of antifungal agents in pediatric patients.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Experiences with the use of caspofungin in paediatric patients.Caspofungin therapy in immunocompromised children and neonates.Antifungal therapy in children: an update.Antifungal agents in current pediatric practice.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibilitIn vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points.Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.Synergy of caspofungin with human polymorphonuclear granulocytes for killing Candida albicansGenome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae.Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
P2860
Q30913384-EB18E208-8882-4E9F-BE9A-B759B3C7111DQ33757912-1046B465-4F49-46B7-A292-E0B44177016DQ33770019-27D249FC-1EBA-4D51-BA7E-2C95DA590728Q33803108-F387B09D-0AD7-48E6-A1BB-BCE275F39A00Q33938068-A5396CA3-E042-46CA-A604-2F01A48B0006Q33983159-66626AC1-D5DA-4D9E-926B-D4B0F3CB4B8EQ34151170-CB7AABD9-2113-4802-B76D-D7A6ED79B775Q34443862-F10409C9-276C-4A9D-AA5A-DD3A64D64E98Q34768471-D35F4BD1-3F3C-4C99-AB22-41AB9A1CE421Q34974761-A431167A-C546-43B1-9192-EFDDB679B88DQ35070838-C4068F97-0A5D-4DB4-B17B-86F094CDA345Q35105398-A4D9AEAC-E0BB-4DEA-A2D8-E9B38D86ADCDQ35122150-6B3ADC0A-FD44-4E6C-9E45-B71D179CABE0Q35598439-EE088AB5-56BE-4A47-A015-B71993C9F299Q35666527-7209C424-1DA3-44C9-8A91-03E0B6958BECQ35738800-9BEC8FCB-5AB6-4BDA-8C0E-1B2EE406AD3DQ36176371-9A2B8C6C-FE45-4D0F-9B32-96C18173E60CQ36285020-CE3AA279-A8A7-4E97-8173-E364F5057C62Q36757591-15191465-3573-4670-9BAA-82FC58A1CC35Q36788428-6059009F-29C7-4A19-8BCA-91194A3F3216Q36821383-191E320B-F046-4BEA-B030-E05E37BDE424Q36968140-F7FB4694-2DBE-4464-B139-CC99807087E5Q37157893-52727B6B-D993-45E2-97D1-ECE323FDACD6Q37159589-76402824-3103-4F9A-BE9A-27FF0A397BCFQ37854725-DAD3C50F-5BF5-4542-859C-8881F52CDA06Q38015090-07646833-8779-4C44-B4AE-9B9CCBA77473Q38101520-445D17AC-4577-4DD3-898D-C7D045DA7BD6Q38215682-C16B6109-CA72-4A42-B4DE-4C90897EAE66Q39665005-54917D41-09CE-4A13-820B-E4AA28FB13AEQ39743420-F6F38606-F119-440C-8F45-44EE331FF668Q40667866-371BC6E0-C9B8-4F40-A528-472592A99F76Q42430266-7A01DE63-4D4E-4119-ADC7-32B7C28FE32EQ44489725-DC2550D1-243B-4CD8-9F62-B94FAAC6AD26Q46592144-296524D6-F0BA-4FA0-BFD5-B0F4DF93FE40Q46653990-627D22CE-C2D5-4E6F-9695-C884E47E4CA5
P2860
Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@ast
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@en
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@nl
type
label
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@ast
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@en
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@nl
prefLabel
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@ast
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@en
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@nl
P2860
P1476
Caspofungin: pharmacology, saf ...... nd invasive fungal infections.
@en
P2093
P2860
P304
P356
10.1517/13543784.10.8.1545
P407
P577
2001-08-01T00:00:00Z